Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Malaysia.
Shanghai Medical College, Fudan University, Shanghai, China.
Expert Opin Investig Drugs. 2023 Jul-Dec;32(7):655-667. doi: 10.1080/13543784.2023.2242773. Epub 2023 Aug 4.
Over three years have passed since the emergence of coronavirus disease 2019 (COVID-19), and yet the treatment for long-COVID, a post-COVID-19 syndrome, remains long overdue. Currently, there is no standardized treatment available for long-COVID, primarily due to the lack of funding for post-acute infection syndromes (PAIS). Nevertheless, the past few years have seen a renewed interest in long-COVID research, with billions of dollars allocated for this purpose. As a result, multiple randomized controlled trials (RCTs) have been funded in the quest to find an effective treatment for long-COVID.
This systematic review identified and evaluated the potential of current drug treatments for long-COVID, examining both completed and ongoing RCTs.
We identified four completed and 22 ongoing RCTs, investigating 22 unique drugs. However, most drugs were deemed to not have high potential for treating long-COVID, according to three pre-specified domains, a testament to the ordeal of treating long-COVID. Given that long-COVID is highly multifaceted with several proposed subtypes, treatments likely need to be tailored accordingly. Currently, rintatolimod appears to have modest to high potential for treating the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subtype, LTY-100 and Treamid for pulmonary fibrosis subtype, and metformin for general long-COVID prevention.
自 2019 年冠状病毒病（COVID-19）出现以来，已经过去了三年多，但 COVID-19 后综合征即长新冠的治疗仍迟迟未决。目前，尚无针对长新冠的标准化治疗方法，主要是因为缺乏对急性后感染综合征（PAIS）的资金支持。然而，过去几年，人们对长新冠研究重新产生了兴趣，为此投入了数十亿美元。因此，为了寻找长新冠的有效治疗方法，已经资助了多项随机对照试验（RCT）。
本系统评价确定并评估了目前用于长新冠治疗的潜在药物治疗方法，同时检查了已完成和正在进行的 RCT。
我们确定了四项已完成和 22 项正在进行的 RCT，研究了 22 种独特的药物。然而，根据三个预先指定的领域，大多数药物被认为对治疗长新冠的潜力不大，这证明了治疗长新冠的艰难。鉴于长新冠具有高度的多面性，有几种提出的亚型，治疗方法可能需要相应地进行调整。目前，利纳西普、LTY-100 和 Treamid 似乎对肌痛性脑脊髓炎/慢性疲劳综合征（ME/CFS）亚型、LTY-100 和 Treamid 对肺纤维化亚型以及二甲双胍对一般长新冠预防具有适度至高度的潜力。
